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Breast cancer is a common diagnosis in women. Breast radiation has become critical in
managing patients who receive breast conserving surgery, or have certain high-risk features
after mastectomy. Most patients have an excellent prognosis, therefore understanding the
late effects of radiation to the chest is important. Radiation-induced heart disease (RIHD)
comprises a spectrum of cardiac pathology including myocardial fibrosis and cardiomyopa-
thy, coronary artery disease, valvular disease, pericardial disease, and arrhythmias. Tissue
fibrosis is a common mediator in RIHD. Multiple pathways converge with both acute and
chronic cellular, molecular, and genetic changes to result in fibrosis. In this article, we review
the pathophysiology of cardiac disease related to radiation therapy to the chest. Our under-
standing of these mechanisms has improved substantially, but much work remains to
further refine radiation delivery techniques and develop therapeutics to battle late effects
of radiation.
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INTRODUCTION
Breast cancer is a common diagnosis in women with an esti-
mated diagnosis of 235,000 new cases made in 2014. Annu-
ally approximately 40,000 women are expected to die from
breast cancer (1). Adjuvant radiation therapy (RT) following
either breast conserving surgery (BCS) or mastectomy has been
shown in comprehensive meta analyses to reduce the risk of
local recurrence by approximately 75%. Unfortunately, RT to
the breast and chest has been associated with radiation-related
morbidity and mortality that may offset some of the benefit of
breast radiation. The spectrum of radiation-induced heart disease
(RIHD) includes pericarditis, cardiomyopathy and myocardial
fibrosis, coronary artery disease, pericardial effusions or constric-
tion, valvular disease, and arrhythmias (2, 3). The spectrum of
RIHD in patients undergoing other thoracic and mediastinal RT
has been described since 1960s. Today, breast cancer patients
likely constitute the largest population of patients exposed to
chest radiation (4, 5). Recently published studies indicating that
breast RT may pose an increased risk of heart disease have re-
emphasized the importance of minimizing the heart dose (6).
Modern techniques including three-dimensional planning, con-
formal blocking, deep-inspiration breath hold, and prone posi-
tioning, among others, have allowed the radiation oncologist to
reduce the heart dose during breast RT, potentially reducing or
eliminating RIHD. In this article, we review the pathophysiol-
ogy of RIHD from several common pathways, and mechanisms
for the specific cardiac pathologies. It is important to know
that RIHD is a heterogenous group of pathologic abnormali-
ties. Substantial work has been performed in histologic descrip-
tion, but further characterization of the biochemical pathways is
required.
NORMAL HEART TISSUE ANATOMY
The heart comprised three layers of tissue: endocardium,
myocardium, and epicardium. The epicardium is superficial outer
layer of the heart composed of a sheet of mesothelial cells. It
is also considered the visceral layer of the serous pericardium.
The epicardium is responsible for producing pericardial fluid that
provides lubrication between the inner serous and outer fibrous
pericardium and protection of the heart from external contu-
sion. Pericardial disease includes pericarditis (inflammation of
the pericardium), pericardial effusion (fluid accumulation in the
pericardial sac), cardiac tamponade (pericardial effusion leading
to hemodynamic compromise), constrictive pericarditis, and other
less common pathologies (4, 7–11). The endocardium most closely
resembles endothelial tissue and lines the inner surface of the heart.
Endothelial cells modulate the function of the cardiac myocytes in
the underlying myocardium. Ventricular endocardium also con-
tains fibers of the cardiac conduction system. The myocardium is
a highly vascular tissue with a capillary density approaching 2800
capillaries per mm2; capillary density of skeletal muscle is approx-
imately 350 capillaries per mm2. Capillaries surround individual
myocytes completely and normally are always open to perfusion.
Prior to initiation of an action potential, cardiac myocytes are in
a resting, well-perfused state. The action potential causes a series
of processes resulting in actin-myosin crossbridging and contrac-
tion. Normally, spontaneous phase 4 depolarization in cells of the
sinoatrial node, the most rapid site of rhythmic discharge, initi-
ates atrial depolarization that propagates via the atrioventricular
nodes, to the His–Purkinje fibers, and to the ventricular myocytes.
The myocardial blood supply is critical and relies on a developed
arteriolar capillary system as there are no major vessels that course
through this tissue. Any radiation-induced damage to the vascular
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endothelial cells that line the myocardial capillaries can result in
decreased myocardial perfusion and poor contractility (12–14).
The major blood supply to the heart is from the coronary arter-
ies. The right and left coronary arteries originate at the root of
the aorta. The left coronary artery divides into the left anterior
descending artery (LAD) and the left circumflex artery. The LAD
is more often implicated in RT-related morbidity as it courses on
the anterior surface of the heart and is most often contacted by
external beam radiation (15, 16). Any disruption to arterial flow,
whether by progressive occlusive disease or acute thrombotic event
causing complete obstruction, can result in ischemia and potential
infarct.
PATHOPHYSIOLOGY OF RADIATION-INDUCED HEART
DAMAGE
A major common endpoint for RIHD is tissue fibrosis. Tissue
irradiation is a major model to study fibrosis (17). In a simple char-
acterization, radiation exposure leads to endothelial cell damage
and subsequent microvascular dysfunction due to fibrosis.
Radiation damage is characterized by both acute and
chronic changes in cardiac tissue. Within minutes of ionizing
radiation, cellular injury causes vasodilation and increased vas-
cular permeability. Damaged endothelial cells secrete adhesion
molecules and growth factors prompting activation of the acute
inflammatory response. Recruited inflammatory cells secrete pro-
fibrotic cytokines (17, 18). Inflammatory cytokines include mono-
cyte chemotactic factor, tumor necrosis factor (TNF), and inter-
leukins (IL) including IL-1, IL-6, and IL-8. The predominant cells
in the acute phase are neutrophils, which become present in all
layers of the heart in RT exposed regions. Within hours of RT, pro-
fibrotic cytokines such as platelet-derived growth factor (PDGF),
transforming growth factor β (TGF-β), basic fibroblast growth
factor (bFGF), insulin-like growth factor (IGF), and connective tis-
sue growth factor (CTGF), among others, are released (19). While
some factors promote recruitment of inflammatory cells and pro-
fibrotic cells, others such as IL-1, act as a tissue radioprotector
(20). Matrix metalloproteinases degrade the endothelial basement
membrane, allowing efficient recruitment of pro-inflammatory
cells to sites of tissue injury to consume injured tissue and initiate
healing. Initial microvascular damage also triggers the coagulation
cascade, resulting in immediate fibrin deposition. The acute phase
courses for several days after RT administration. Following this
acute infiltration, there exists a quiescent period where there are
no obvious microscopic changes in the tissue (21).
The acute pro-inflammatory environment is a powerful initia-
tor of fibrosis (19). Fibroblasts are recruited from a number of
different sources: derived from mesenchymal cells, recruited from
bone marrow, or sourced from epithelial–mesenchymal cell tran-
sition. These changes are characterized by collagen deposition and
endothelial cell proliferation. Extracellular matrix deposition by
fibroblasts results in late pathologic dysfunction of myocytes, vas-
cular endothelial cells, and the pericardium (Figure 1). Aside from
the acute inflammatory response, there is an immediate expression
of proto-oncogenes including c-myc and c-jun, which may prompt
late fibrotic changes (22, 23). Multiple mediators ultimately
result in long-term recruitment of matrix metalloproteinases,
inflammatory mediators such as IL-4, IL-13, and TGF-β, and
smooth muscle cell proliferation. IL-13 is a known potent fibrotic
mediator produced by inflammatory T cells and in certain mouse
models, IL-13 knockouts do not experience fibrosis (17). TGF-β
is known as a fibroblast mediator and can induce fibroblast dif-
ferentiation. TGF-β can alter the balance of extracellular matrix
remodeling to induce collagen synthesis, decrease production of
collagenase and other proteases, and increase the production of
protease inhibitors. TGF-β has a multitude of effects and its
expression is continues in irradiated tissues (24). After myofi-
broblasts have been activated, collagen deposition and fibroblast
differentiation can continue independent of TGF-β signaling by
autocrine induction (19, 22). Chronic oxidative stress with free
radical production and this persistent pro-inflammatory facilitate
the development of late atherosclerotic disease.
It is already well-known that tissue irradiation ultimately leads
to fibrosis; however, radiation changes the biology of pro-fibrotic
cells. Ionizing radiation induces premature differentiation of
fibroblasts. In normal fibroblast differentiation, 25–35 cell division
cycles are required. After ionizing radiation, progenitor fibrob-
lasts differentiate into post-mitotic fibroblasts within 2–3 weeks,
representing only 3–4 cell cycles. The lifespan of these termi-
nally differentiated radiation-induced fibrocytes is nearly 40–45%
shorter than naturally differentiated cells. These post-mitotic cells
are shown to be five to eight times more active in the produc-
tion of interstitial collagens I, III, and IV compared to progenitor
fibroblasts. Ionizing radiation, on its own, can induce premature
terminal differentiation of progenitor fibroblasts to post-mitotic
fibrocytes that are more active in collagen deposition (25, 26).
Myofibroblasts are permanently activated in these tissues even
after repair of initial damage, unlike in normal wound repair (27).
Chronic deposition of collagen and other components of other
extracellular matrix components can produce a fibrotic scar reduc-
ing functionality of the affected tissue. Pathologic examination of
these lesions show elevated inflammatory cells, fibroblasts, and
excessive extracellular matrix, such as collagens, proteoglycans,
and fibronectin.
The inflammatory pathway is likely the predominant pro-
fibrotic mediator, but other pathways contribute significantly.
Another mediator is chronic oxidative stress, the result of chronic
free radical production. The oxidative stress simultaneously
increases inflammatory mediators, proteases, and adhesion mole-
cules, and decreases nitric oxide, a vascular protectant that blocks
platelet aggregation and vascular smooth muscle proliferation.
Nuclear factor-kappa B (NF-κB), a protein complex that regulates
DNA transcription and is involved in cellular response to vari-
ous stresses, may serve as a key link between oxidative stress and
inflammatory pathways (Figure 2). In a study of irradiated human
neck arteries, NF-κB is chronically upregulated locally in irradi-
ated human arterial vascular cells anywhere from 4 to 500 weeks
after treatment (28, 29).
In addition to NF-κB, other changes in gene expression medi-
ate a pro-fibrotic environment. Chronic hypoxia from microves-
sel damage leads to upregulation of hypoxia inducible factor α
(HIF1-α), which is another stimulator of TGF-β (19). This pro-
vides further evidence how local radiation can result in chronic
gene expression changes leading to long term and late pathology
(28, 29).
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FIGURE 1 | Wound healing and fibrosis in tissue (17).
Fibrosis is both acute and late effect of tissue irradiation. It is the
result of multiple converging pathways including inflammation,
oxidative stress, and chronic changes in gene expression (Figure 3).
There is broad involvement of the DNA damage response, TGF-β
signaling, and the chronic inflammatory pathways. Acute changes
largely result from direct radiation damage and the immediate
inflammatory response. Long-term changes in the tissue and char-
acterization of characterization of epigenetic changes, altered cell
signaling, and stem cell loss are critical to understanding late and
persistent fibrosis (27). The incredibly complex interplay between
multiple converging pathways may lead to a variety of clinical
targets to combat fibrosis. However, many of these targets have
pleiotropic effects leading to other toxicity, and knocking down a
single pro-fibrotic pathway may not be sufficient to show clinical
benefit.
CORONARY ARTERY DISEASE
The initiation of RIHD in the coronary arteries is similar to
that of most other tissues as radiation leads to microvascular
damage, inflammation, and subsequent fibrosis. In general, the
pathologic changes observed in RIHD are morphologically simi-
lar to atherosclerotic disease in medium and large vessels (100–500
and >500µm, respectively) (30). In small-sized arteries, there
is often subendothelial fibrosis, accumulation of acellular col-
lagenous material in the media, and accumulation of lipid-laden
macrophages (foam cells) in the intima (31). In medium-sized
arteries, foam cells, fibroblasts, and collagen accumulate in the
intima. Occasionally, there is acute vasculitis with a predomi-
nantly lymphocytic rich infiltrate in the media and adventitia.
It is presumed this pathology is self-limited based on animal mod-
els. In one swine study with coronary and iliac arteries subjected
to P32 endovascular brachytherapy, 51% of arterioles sampled
near exposed coronary arteries and 100% of arterioles near iliac
arteries had evidence of vasculitis in doses from 6 to 40 Gy at
28 days post-exposure. This was noted to be morphologically dis-
similar than other systemic vasculitides (32). The smooth muscle
layer in the arteries is noted to be replaced instead by fibrous
tissue (33). Large arteries are not as often affected as smaller
vessels, given that a large luminal diameter allows for larger
plaque accumulation before clinical evidence of disease, and thick
walled vessels may have more radioresistant cells. However, large
radiation-associated plaques with concomitant underlying ath-
erosclerotic disease can lead to plaque rupture and thrombosis
(Figure 4).
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The endothelial cells respond with inflammatory markers and
adhesion molecules to recruit peripheral leukocytes with doses
as little as ≥2 Gy. Once monocytes enter the subendothelial
FIGURE 2 | Proposed mechanism of involvement of NF-κB in
radiation-induced vascular disease (28)
.
space, they may transform into activated macrophages. Activated
macrophages can ingest lipids, forming fatty streak in the intima
leading to early atherosclerotic lesions. Late proliferation of myofi-
broblasts can further the growth of these luminal-narrowing
lesions. Dose of RT ≥8 Gy are associated with increased size
and number of these lesions in the major arteries. In addition,
the plaques that result may be more unstable and macrophage-
laden (34). Unlike stable collagenous plaques, radiation-related
plaques tend to grow, rupture, and lead to a myocardial infarc-
tion or cerebrovascular accident more often (35). It is impor-
tant to note that these dose–response data include series from
in vitro models and limited autopsy assessment. Although the data
appear to confirm clinical suspicion, further assessment would be
FIGURE 4 | Significant fibrosis of the left anterior descending (LAD)
artery after chest radiation (58).
FIGURE 3 | Overview of complex pathways in tissue fibrosis (27).
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required particularly in the era of modern radiation techniques
with different dose constraints and refined treatment planning.
The arteries affected and plaque location differs from usual ath-
erosclerotic disease. Compared to usual atherosclerotic disease, the
LAD artery tends to be often involved in RIHD. This may be due
to RT biased toward involvement of the anterior chest. Lesions in
RIHD tend to involve a longer length of artery than usual athero-
sclerotic plaques. Maximum luminal narrowing tends to be at the
distal ends of the lesions, and often at arterial bifurcations (16).
Arterial fibrosis is a well-studied phenomenon in RIHD and
radiation exposure is an independent risk factor for long-term
cardiovascular disease. This is apparent in early stage breast can-
cer, Hodgkin’s disease, and other childhood cancer. There is epi-
demiologic evidence associating high-dose exposure with cardiac
morbidity, including coronary artery disease (2, 36, 37). The dose–
response relationship leading to clinically meaningful morbidity
is still poorly understood, particularly with low-dose radiation
exposure. Preclinical data report that dose of 2 Gy does not alter
vessel phenotype in moderate-term followup and ultra-low-dose
exposure of<0.5 Gy can even have anti-atherosclerotic effect (38).
However, new clinical data in breast cancer survivors suggest that
there is no low-dose threshold that increases the risk of RIHD (6).
Conventional and three-dimensional RT (3DCRT) has given way
to newer technologies such as intensity-modulated radiation ther-
apy (IMRT) that offers increasing dose homogeneity in the target
volume with potential for normal tissue sparing. It remains an
open question what effect spreading of low-dose radiation with
IMRT from multiple beam angles will have on atherosclerotic
disease.
MYOCARDIAL FIBROSIS AND CARDIOMYOPATHY
The myocardial subunit is composed of cardiac myocytes, capil-
laries, and stromal tissue. Each myocardial subunit has a network
of capillaries and relies on diffusion for nutrient metabolism, as
there are no arterioles in the tissue. Damage to the myocardium
occurs after capillary loss from radiation-induced microvascu-
lature damage. Decrease in capillary density results in islands
of hypoxia in the myocardial tissue (18). In a study by Fajardo
and Stewart, it was noted that 100 days after RT exposure, there
was a significant reduction in the ratio of capillaries to cardiac
myocytes. There was also endothelial cell membrane alteration
with subsequent microthrombus formation (34). There may be
some compensatory transient capillary proliferation; however, this
largely appears to be inadequate to compensate for progressive and
chronic microvascular damage.
Microvascular damage also leads to inflammatory and pro-
thrombotic changes. After cell damage and death, pathologic
changes are indicative of progressive fibrosis replacing myocardial
tissue. Chello et al. conducted an autopsy study of normal heart
tissue compared to left ventricular tissue of patients with post-
radiation pericarditis. In the ventricular tissue of irradiated hearts,
there was a significant increase in total tissue collagen concentra-
tion compared to non-irradiated hearts, consistent with long-term
fibrosis. Both Type I and Type III collagen were increased; however,
there was a disproportionate increase in the amount of Type I col-
lagen. Type I is more often found in repair tissue whereas Type
III collagen is more often found acutely in granulation tissue.
This may lead to decreased distension of the ventricles during
filling (39).
Progressive fibrosis of the myocardium ultimately leads to
decrease in tissue elasticity and distensibility, particularly after
replacement with Type I collagen. This leads to reduction in ejec-
tion fraction and increase in left ventricular end-diastolic volume
and reduced ejection fraction. Marks et al. conducted a study of
114 patients with left sided breast cancer designed to study changes
in regional and global cardiac function using technetium-99m ses-
tamibi or tetrofosmin scans before and after breast radiation. At 6,
12, 18, and 24 months, 27, 29, 38, and 42% of patients, respectively,
had new perfusion defects. These patients with perfusion defects
were also more likely to have regional wall motion abnormali-
ties (40). This suggests that microvascular damage leads to tissue
fibrosis with clinically detectable cardiac function. The final out-
come is that irradiation ultimately results in loss of tissue elasticity.
This pertains primarily to the ventricles rather than the coronary
arteries.
The cardiovascular system responds differently to RT-related
myocardial damage compared with ischemia-related heart fail-
ure. In RT-unrelated myocardial damage, the body activates the
sympathetic nervous system continuously, while simultaneously
down-regulating β-adrenergic receptors. In contrast, RT-related
myocardial damage results in no augmentation of the sympathetic
nervous system in the adrenal glands, but β-receptors initially are
upregulated in the heart. This upregulation of the receptors may
allow the heart to stabilize cardiac output despite damage. Even-
tually, as damage progresses, further reductions in cardiac output
occur near the onset of congestive heart failure (41–43).
Fibrosis dominates both atherosclerotic disease and myocardial
damage. There is similar debate regarding the relative contribu-
tion of low-dose radiation to clinical apparent cardiac morbidity.
High-dose radiation exposure to the left ventricle can be obviated
by a variety of heart sparing radiation techniques such as multileaf
collimator (MLC) or cerrobend blocking, deep inspiration breath
hold, or prone positioning. However, some low-dose exposure is
unavoidable. Cardiac perfusion imaging studies have yet to show
perfusion defects in areas with low exposure (heart Dmean < 5 Gy
or doses of 0–10 Gy) (44, 45). This remains a very active area of
study, but it is advisable to keep heart dose as low as reasonably
possible particularly in the era of cardiotoxic systemic therapy.
VALVULAR DISEASE
Valvular disease is less well characterized compared to changes in
the myocardium and coronary arteries. Fibrotic damage in the
valves is unlikely related to microvascular damage as the heart
valves are avascular. The damage is likely related to other myocar-
dial disease. In one example, RT-related dilated cardiomyopathy
may induce regurgitation, although the exact mechanism is poorly
understood. Although valvular disease has a high incidence of
pathologic changes, the majority of patients do not appear to
have more than moderate clinical symptoms (33, 46). One post-
mortem series of patients who received at least 35 Gy to heart
indicated up to 81% (13 of 16) of patients showed evidence of
valvular dysfunction and fibrosis, without or without dystrophic
calcification. Specimens showed focal thickening of the valvular
endocardium by elastic fibers (33). Veinot conducted a study of
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27 patients with multiple cardiac tissue specimens. These patients
represented breast cancer, as well as lymphomas and other tho-
racic cancers. A clear majority of patients experienced RT-related
valvular disease with a mean dose of 46 Gy. There was a signifi-
cant latent period before the development of valvular symptoms
with mean time at 98 months. All the valves showed diffuse cusp or
leaflet fibrosis. There were no changes indicative of chronic inflam-
mation or neovascularization, suggesting that another RT-related
mechanism drives valvular pathology. There was a spectrum of
mild to severe stenosis or incompetency (46). Although available
series indicate a significant percentage affected with valvular dis-
ease, the incidence may likely be lower in often used tangent breast
radiation given a significantly lower dose to the heart compared to
thoracic or mediastinal radiation.
PERICARDIAL DISEASE
Up to 70–90% of patients with significant mediastinal radiation
exposure may have evidence of pericardial disease (33, 46). In
pathologic cardiac specimens after >35 Gy to the heart in young
patients aged 15–33, 15/16 had thickened pericardia. Of these,
five patients had pericardial tamponade (33). Initial series of
Hodgkin’s disease patients indicated up to 40% of patients expe-
rienced clinical pericarditis. Use of reduced total and daily doses,
as well as conformal techniques has reduced this risk nearly to 2%
(21, 47). The incidence in breast radiation is likely even lower given
the limited dose to the heart compared to mediastinal radiation.
There is both acute and late pericardial injury present, driven
by inflammation and immediate fibrin deposition. Initial injury
to the pericardium is due to microvascular damage that leads
to episodic ischemia. Tortuous and permeable neovascularization
occurs in irradiated pericardium, leading to additional ischemia
and late fibrosis. Additional fibrosis of venous and lymphatic chan-
nels in the heart decreases the ability to drain extracellular fluid,
leading to accumulation of a fibrin-rich exudate (21). Early clinical
pericardial disease is generally represented by effusions (46).
Nearly 20% of patients who experienced late significant fibrosis
of the pericardium may have initially had effusions (21). Fibrinous
exudates on the visceral pericardium are later replaced by fibrob-
lasts laying down collagen, leading to long-term fibrosis of the
pericardium. Normal pericardial adipose tissue is replaced by col-
lagen and fibrin. An increase in Type I collagen deposited in the
pericardium decreases diastolic compliance of the ventricles, and
the pericardium can be thickened from 1 to 7 mm in severe disease
after radiation (39, 46). These changes can lead to a spectrum of
pericardial pathologies including acute and delayed pericarditis,
pancarditis, and possible severe constrictive pericarditis, result-
ing in tamponade (48). In Veinot’s series, patients who were
found to have significant constriction became symptomatic after
18 months, suggesting a long latent period after exposure (46).
CARDIAC ARRHYTHMIAS
Conduction system abnormalities are not as well-documented or
reported as the other cardiac pathologies. Arrythmias are likely due
to microvascular damage, leading to cardiac myocyte conduction
abnormalities or direct damage to critical structures such as the
sinoatrial or atrio-ventricular nodes. This may result in AV-nodal
bradycardia or all types of heart block, including complete heart
block. Right bundle branch block has been observed, due to either
direct damage to the conducting myocytes or adjacent microvas-
cular damage resulting in ischemia. In a series of three Hodgkin’s
lymphoma patients treated nearly 10 years prior with mantle
radiation, two of the three had partial or complete right bun-
dle branch block before the age of 35 (49). Fibrosis of the left
ventricular wall is associated with increased ventricular ectopy.
Nearly 12 years after thoracic irradiation, a report of six patients
all showed complete atrio-ventricular node block requiring per-
manent pacemaker implantation. Of the six patients, five had
right bundle branch block or alternating right bundle branch
block. The mean RT dose was 52 Gy (50). As expected, all of
these patients had multiple other pathologies, including myocar-
dial fibrosis, pericardial disease, and coronary artery disease. In a
series of nearly 200 breast cancer survivors, a significant percentage
had conduction abnormalities at both 6 months and 10 years after
treatment. Nineteen percent of patients had pre-treatment con-
duction abnormalities, which increased to 45% at both 6 months
and 10 years after therapy. The predominant changes at 6 months
were T wave abnormalities in left sided breast cancer patients. At
10 months, there were fewer T wave changes, but increased ST
depression. Although present in a large percentage of breast can-
cer patients, these changes were largely reversible and clinically
insignificant (51).
Ventricular ectopic beats (VEB) are commonly seen in
outpatient medicine and are often benign. These include often
asymptomatic premature ventricular contractions (PVC) to more
dangerous ventricular tachycardia and ventricular fibrillation. The
incidence is nearly 1% in clinically normal people using electro-
cardiogram (ECG) detection, and up to 75% in clinically well
patients using Holter monitoring (52, 53). Although chest radia-
tion may increase the incidence of VEB, a comprehensive assess-
ment must first be performed to rule out other exacerbating factors
such as ischemic heart disease, structural heart disease, substance
ingestion, or smoking.
To suggest that AV abnormalities may be related to prior RT,
one series suggests the following criteria be met (1) total RT dose
to the heart>40 Gy (2) latency of>10 years since RT (3) an abnor-
mal interval ECG (4) prior pericardial involvement (5) associated
cardiac or mediastinal disease (54). However, these criteria would
not often be met in breast cancer survivors. In long-term survivors,
vigilance will be required in patients who have experienced other
RIHD pathologies or who have underlying atherosclerotic disease.
There must be great care in attributing arrhythmias to RT versus
competing causes.
FUTURE DIRECTIONS
There exist clear mechanisms by which RT leads to acute and long-
term changes in cardiac tissue. Pathologic changes after radiation
exposure with clinical implication have been well-documented.
However, there are a tremendous number of unanswered questions
that will be critical in understanding, prevention, and treatment
of RIHD. The bulk of damage appears to be from acute and
chronic inflammatory changes, but persistent oxidative stress and
genetic changes also significantly contribute. It will be impor-
tant to characterize the relative contribution of each pathway to
evaluate, which will be the most meaningful target of therapeutics.
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High-dose radiation exposure is clearly associated with cardiac
toxicity; however, the contribution of low-dose radiation is not
completely characterized. In addition, it is even unclear if there is
a low-dose threshold before which clinically meaningful morbid-
ity appears. The relative contribution of high-dose and low-dose
radiation exposure may be augmented further by cardiotoxic sys-
temic therapy such as anthracycline chemotherapy, or underlying
patient comorbidities such as diabetes, pre-existing heart disease,
and smoking.
Given the multiple pathways leading to RIHD, there are a
number of potential therapeutic targets. These include anti-
inflammatory mediators, anti-fibrotics, genetic modulators, and
even stem cell treatment (55–57). Studies have largely been preclin-
ical, to date, and therapeutics are either in clinical trials or under
development. However, establishment of an excellent therapeu-
tic would likely require large numbers of patients with extensive
long-term follow-up.
CONCLUSION
Radiation-induced heart disease represents a collection of cardiac
pathology including coronary artery disease, myocardial fibro-
sis, pericardial disease, arrhythmias, and valvular abnormalities.
There are several common pathways involved in the develop-
ment of RIHD including microvascular damage, inflammation,
and fibrosis, although other pathways contribute. The interac-
tion of multiple biochemical markers and cytokines such as
TGF-β and interleukins, drive a significant portion of chronic
inflammation and late fibrosis. Although there exist substantial
evidence RIHD has a significant incidence and can lead to sub-
stantial morbidity, the exact mechanisms of the various RIHD
pathologies are not entirely understood. The development of ther-
apeutic targets to prevent microvascular damage, inflammation,
and late fibrosis will hinge on our increased understanding of
RIHD.
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